Clinical trials patient Mr Sin |
Monash Haematology researchers have demonstrated that
clinical trials not only benefit patients but provide a significant financial
boost to the hospital system as well.
The Haematology Research Unit at Monash Health provides
treatment and follow up care for nearly 400 patients every year, many
participating in clinical trials.
“We treat a wide variety of blood cancer and non-cancer haematology
patients, including chronic lymphocytic leukaemia, follicular lymphoma, B cell
lymphoma, myelodysplastic syndrome, Waldenstrom’s macroglobulinaemia, chronic
and acute myeloid leukemia, T cell lymphoma and more,” said Head of the
Department of Haematology Professor Stephen Opat.
A recent report by the Haematology Research Unit shows that
providing clinical trials to patients has a positive effect on Monash Health’s
bottom line, as well as offering cutting-edge treatments that may not otherwise
be available.
Mr Sin with Clinical Trials Coordinator Ms Liz Coughlin |
Monash Haematology patient Mr Yoeun Sin has Waldenstrom
Macroblobulinemia, a type of non-Hodgkin lymphoma. Mr Sin is the first patient
in the world to receive an experimental drug (BGB3111) to treat the disease.
Professor
Opat said Mr Sin is a typical Monash patient whose previous two treatments had
failed, and thanks to the clinical
trial, his experimental treatment had been life changing.
“I
feel very honoured and grateful for being the first person to receive
BGB3111—without this drug I’m not too sure where or how I’d be in terms of
health,” said Mr Sin.
Mr
Sin said the opportunity to take part in the clinical trial has given him
another chance at life.
“I
now feel full of life and filled with energy. Taking BGB3111 has given me the
opportunity to do more with the amount of time I have left...which I hope is a
long time,” he said.
Professor Opat said the Haematology Research Unit operates
on a self-funded model, supporting the wages of all staff and covering all
treatment and follow-up care related costs of patients.
“The patients treated or managed in our unit are in effect,
taken out of the Monash Health care network in relation to the costs that would
normally be associated with their treatment and care,” said Professor Opat.
In order to demonstrate their savings, the Haematology
Research Unit selected 25 patients who were treated and commenced follow up for
various haematological malignancies in the 2015-2016 financial year, and
calculated the costs that would have been associated with these patients had
they received standard of care treatment through the public health system at
Monash Health.
Professor Opat said that by treating, and providing follow
up care for this selection of 25 patients, the Haematology Research Unit
relieved the Health care network of $843,363.80 of funding that would be
required to care for these patients over their treatment and standard 5 year
follow up periods.
“$759,333 of this cost is relieved in the first year while
patients are having treatment, and $713,862 being pharmacy related costs.”
“Our Unit in fact treated and provided follow up care for 86
patients with haematological malignancies in the 2015-2016 financial year, so
we estimate the financial relief to Monash Health for the treatment period
alone, could be as high as $2,612,105,” said Professor Opat.
These figures don’t take into account the further financial
benefit due to the treatment, management and care of the 254 non-oncology
haematology patients during the same period.
Professor Opat said he is exceptionally proud of the work
that his Unit continues to do, the quality with which we do it, and the savings
that we continue to make toward the health care network.
Haematology
Clinical Trial Unit Managers Ms Micheleine Uhe and Ms Jeanette Gamgee attribute
the success of the Unit to the dedication of their extremely efficient and
hard-working team.
No comments:
Post a Comment